Choose a language and wait for the translated text.
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed monitoring of the implementation of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, notified through a Gazette Order dated 17 October 2026. The revised prices came into effect on 9 November 2026.
The latest revised price lists, based on submissions received from companies up to 11 November 2026, are available on the NPPA website and the Pharma Sahi Daam app/portal. Manufacturers, retailers, dealers, stockists, hospitals and medical institutions have been directed to comply with the revised prices and display the updated price lists at their premises and websites.
State Drug Controllers (SDCs) have been directed to monitor compliance by manufacturers, dealers, hospitals and medical institutions to ensure that the benefits of revised maximum retail prices (MRPs) are passed on to patients. Any violation may attract overcharging proceedings under the provisions of the Drugs (Prices Control) Order (DPCO), 2013.
Complaints regarding overcharging, shortage or non-availability of medicines can be reported through the Pharma Sahi Daam app/portal, NPPA helpline (1800-111-255) or email (monitoring-nppa[at]gov[dot]in).
State Drug Controllers have been asked to submit their Action Taken Reports to NPPA by 16 November 2026.
The post NPPA directs monitoring of trade margin rationalisation on 137 anti-cancer drugs appeared first on Express Pharma.
